A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. The metric has seen a significant loss of -2.77% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -2.65%. Over the past 30 days, the price of CTSO has leaped by -6.86%. And in the last five days, it has fallen by -1.69%.
Cytosorbents Corp ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $1.59 on 09/30/24, while the lowest value for the same period was recorded at $0.70 on 07/01/24.
52-week price history of CTSO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cytosorbents Corp’s current trading price is -44.35% away from its 52-week high, while its distance from the 52-week low is 26.40%. The stock’s price range during this period has varied between$0.70 and $1.59. The Cytosorbents Corp’s shares, which operate in the Healthcare, saw a trading volume of around 5.72 million for the day, a figure considerably higher than their average daily volume of 0.14 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cytosorbents Corp (CTSO) has experienced a quarterly decline of -28.07% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 48.51M and boasts a workforce of 186 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.0380, with a change in price of -0.0281. Similarly, Cytosorbents Corp recorded 175,630 in trading volume during the last 100 days, posting a change of -3.15%.
CTSO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CTSO stands at 2.06. Similarly, the long-term debt-to-equity ratio is also 2.03.
CTSO Stock Stochastic Average
Cytosorbents Corp’s raw stochastic average for the past 50 days is presently 40.27%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 21.11%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 33.14% and 35.99%, respectively.
